Pooled estimates of clinical events in studies comparing DOACs vs warfarin in patients with concomitant CKD and AF
| . | Total patients, n . | OR, events per test period . | Heterogeneity . | |||
|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | Q test, P value . | Higgins I2, % . | ||
| No. of bleeds | ||||||
| Overall bleeds | ||||||
| RCTs | 36 840 | 0.78 | 0.59-1.04 | .09 | <.01 | 85 |
| Non-RCTs | 246 301 | 0.66 | 0.49-0.88 | <.01 | <.01 | 97 |
| RCTs (apixaban only) | 20 647 | 0.64 | 0.55-0.75 | <.01 | .32 | 13 |
| Non-RCTs (apixaban only) | 48 091 | 0.52 | 0.44-0.63 | <.01 | .09 | 43 |
| Non-RCTs (dabigatran only) | 42 120 | 0.74 | 0.53-1.02 | .07 | <.01 | 76 |
| RCTs (rivaroxaban only) | 3 940 | 0.93 | 0.73-1.18 | .56 | .76 | 0 |
| Non-RCTs (rivaroxaban only) | 50 725 | 0.79 | 0.71-0.87 | <.01 | .02 | 66 |
| GI bleeds | ||||||
| Non-RCTs | 48 705 | 0.68 | 0.50-0.92 | .01 | <.01 | 75 |
| Intracranial bleeds | ||||||
| RCTs | 15 203 | 0.91 | 0.63-1.31 | .61 | .26 | 26 |
| Non-RCTs | 33 917 | 0.52 | 0.36-0.76 | <.01 | .82 | 0 |
| Stroke incidence | ||||||
| RCTs | 26 076 | 0.76 | 0.66-0.87 | <.01 | .54 | 0 |
| Non-RCTs | 163 035 | 0.60 | 0.43-0.85 | <.01 | <.01 | 94 |
| RCTs (apixaban only) | 21 405 | 0.71 | 0.61-0.83 | <.01 | .70 | 0 |
| Non-RCTs (apixaban only) | 22 144 | 0.60 | 0.41-0.87 | <.01 | .63 | 0 |
| Non-RCTs (dabigatran only) | 26 805 | 0.97 | 0.44-2.13 | .94 | .07 | 69 |
| RCTs (rivaroxaban only) | 4 120 | 0.94 | 0.69-1.29 | .71 | .50 | 0 |
| Non-RCTs (rivaroxaban only) | 43 892 | 0.56 | 0.38-0.83 | <.01 | <.01 | 74 |
| Systemic/arterial embolism | ||||||
| Non-RCTs | 47 641 | 0.49 | 0.13-1.81 | .28 | <.01 | 82 |
| All-cause mortality | ||||||
| RCTs | 31 886 | 0.87 | 0.78-0.97 | .01 | .57 | 0 |
| Non-RCTs | 121 728 | 0.74 | 0.65-0.84 | <.01 | <.01 | 68 |
| . | Total patients, n . | OR, events per test period . | Heterogeneity . | |||
|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | Q test, P value . | Higgins I2, % . | ||
| No. of bleeds | ||||||
| Overall bleeds | ||||||
| RCTs | 36 840 | 0.78 | 0.59-1.04 | .09 | <.01 | 85 |
| Non-RCTs | 246 301 | 0.66 | 0.49-0.88 | <.01 | <.01 | 97 |
| RCTs (apixaban only) | 20 647 | 0.64 | 0.55-0.75 | <.01 | .32 | 13 |
| Non-RCTs (apixaban only) | 48 091 | 0.52 | 0.44-0.63 | <.01 | .09 | 43 |
| Non-RCTs (dabigatran only) | 42 120 | 0.74 | 0.53-1.02 | .07 | <.01 | 76 |
| RCTs (rivaroxaban only) | 3 940 | 0.93 | 0.73-1.18 | .56 | .76 | 0 |
| Non-RCTs (rivaroxaban only) | 50 725 | 0.79 | 0.71-0.87 | <.01 | .02 | 66 |
| GI bleeds | ||||||
| Non-RCTs | 48 705 | 0.68 | 0.50-0.92 | .01 | <.01 | 75 |
| Intracranial bleeds | ||||||
| RCTs | 15 203 | 0.91 | 0.63-1.31 | .61 | .26 | 26 |
| Non-RCTs | 33 917 | 0.52 | 0.36-0.76 | <.01 | .82 | 0 |
| Stroke incidence | ||||||
| RCTs | 26 076 | 0.76 | 0.66-0.87 | <.01 | .54 | 0 |
| Non-RCTs | 163 035 | 0.60 | 0.43-0.85 | <.01 | <.01 | 94 |
| RCTs (apixaban only) | 21 405 | 0.71 | 0.61-0.83 | <.01 | .70 | 0 |
| Non-RCTs (apixaban only) | 22 144 | 0.60 | 0.41-0.87 | <.01 | .63 | 0 |
| Non-RCTs (dabigatran only) | 26 805 | 0.97 | 0.44-2.13 | .94 | .07 | 69 |
| RCTs (rivaroxaban only) | 4 120 | 0.94 | 0.69-1.29 | .71 | .50 | 0 |
| Non-RCTs (rivaroxaban only) | 43 892 | 0.56 | 0.38-0.83 | <.01 | <.01 | 74 |
| Systemic/arterial embolism | ||||||
| Non-RCTs | 47 641 | 0.49 | 0.13-1.81 | .28 | <.01 | 82 |
| All-cause mortality | ||||||
| RCTs | 31 886 | 0.87 | 0.78-0.97 | .01 | .57 | 0 |
| Non-RCTs | 121 728 | 0.74 | 0.65-0.84 | <.01 | <.01 | 68 |
Unless a specific DOAC is indicated in brackets (apixaban, edoxaban, or rivaroxaban only), the result represents a pooled estimate for all DOACs.